, Réseau Epidémiologie et Information en Néphrologie (REIN) -Rapport annuel 2015

S. Beaudreuil, H. Hebibi, B. Charpentier, and A. Durrbachr, Les infections graves chez les patients en dialyse péritonéale et en hémodialyse chronique conventionnelle : péritonites et infections de la voie d'abord vasculaire, Réanimation, vol.17, issue.3, pp.233-241, 2008.

M. J. Sarnak and B. L. Jaber, Mortality caused by sepsis in patients with end-stage renal disease compared with the general population, Kidney Int, vol.58, pp.1758-64, 2000.

R. D. Moore, P. S. Lieteman, and C. R. Smith, Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration, J Infect Dis, vol.155, issue.1, pp.93-102, 1987.

A. D. Kashuba, A. N. Nafziger, G. L. Drusano, and J. S. Bertino, Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria, Antimicrob Agents Chemother, vol.43, issue.3, pp.623-632, 1999.

J. Blaser, B. B. Stone, M. C. Groner, and S. H. Zinner, Comparative study with enoxacin and

A. Chemother, , vol.31, pp.1054-60, 1987.

D. S. Burgess, Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance, Chest, vol.115, pp.19-23, 1999.

A. Rapport and . Mars, Bon usage des aminosides administrés par voie injectable gentamicine, tobramycine, nétilmicine, amikacine -Mise au point, 2011.

G. R. Aronoff, W. M. Bennett, and J. S. Berns, Drug Prescribing in Renal Failure 5

P. A. Philadelphia, American College of Physicians, 2007.

H. Matsuo, J. Hayashi, K. Ono, K. Andoh, Y. Andoh et al., Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality, Antimicrob Agents Chemother, vol.41, issue.12, pp.2597-601, 1997.

K. M. Sowinski, S. J. Magner, A. Lucksiri, M. K. Scott, R. J. Hamburger et al., Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing, Clin J Am Soc Nephrol, vol.3, issue.2, pp.355-61, 2008.

L. Dang and S. Duffull, Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis, J Clin Pharmacol, 2006.

M. M. Teigen, S. Duffull, L. Dang, and D. W. Johnson, Dosing of gentamicin in patients with endstage renal disease receiving hemodialysis, J Clin Pharmacol, vol.46, issue.11, pp.1259-67, 2006.

S. O'shea, S. Duffull, and D. W. Johnson, Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate ?, Semin Dial, vol.22, issue.3, pp.225-255, 2009.

L. Zhuang, Y. He, H. Xia, Y. Liu, S. K. Sy et al., Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semimechanistic pharmacokinetic/pharmacodynamic model, J Antimicrob Chemother, 2016.

, MIC and zone diameter distributions and ECOFFs

A. Veinstein, N. Venisse, J. Badin, M. Pinsard, R. Robert et al., Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered, Antimicrob Agents Chemother, vol.57, issue.2, pp.977-82, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00944357

N. Allou, A. J. Levy, Y. Bouteau, A. Caujolle, M. Delmas et al., Assessment of the National French recommendations regarding the dosing regimen of 8mg/kg of gentamicin in patients hospitalised in intensive care units, Anaesth Crit Care Pain Med, 2016.

E. De-montmollin, L. Bouadma, N. Gault, B. Mourvillier, E. Mariotte et al.,

, mg/kg total body weight regimen, vol.40, pp.998-1005, 2014.

F. S. Taccone, P. F. Laterre, H. Spapen, T. Dugernier, I. Delattre et al., Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock, Crit Care, 2010.

R. Gálvez, C. Luengo, R. Cornejo, J. Kosche, C. Romero et al., Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity, Int J Antimicrob Agents, vol.38, issue.2, pp.146-51, 2011.

C. Roger, B. Nucci, N. Molinari, S. Bastide, G. Saissi et al.,

, Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentration, Int J Antimicrob Agents, vol.46, issue.1, pp.21-28, 2015.

M. Bouras, L. Floch, R. Asehnoune, K. Roquilly, and A. , Administration des antibiotiques en réanimation, Congrès d'actualisation SFAR 2017

. Bibliographie,

, Réseau Epidémiologie et Information en Néphrologie -Rapport annuel 2015

M. J. Sarnak and B. L. Jaber, Mortality caused by sepsis in patients with end-stage renal disease compared with the general population, Kidney Int, vol.58, pp.1758-64, 2000.

S. Beaudreuil, H. Hebibi, B. Charpentier, and A. Durrbachr, Les infections graves chez les patients en dialyse péritonéale et en hémodialyse chronique conventionnelle : péritonites et infections de la voie d'abord vasculaire, Réanimation, vol.17, issue.3, pp.233-241, 2008.

J. A. Roberts, Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions, Lancet Infect Dis, vol.14, issue.6, pp.498-509, 2014.

R. D. Moore, P. S. Lieteman, and C. R. Smith, Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration, J Infect Dis, vol.155, issue.1, pp.93-102, 1987.

A. D. Kashuba, A. N. Nafziger, G. L. Drusano, and J. S. Bertino, Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria, Antimicrob Agents Chemother, vol.43, issue.3, pp.623-632, 1999.

J. Blaser, B. B. Stone, M. C. Groner, and S. H. Zinner, Comparative study with enoxacin and

A. Chemother, , vol.31, pp.1054-60, 1987.

D. S. Burgess, Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance, Chest, vol.115, pp.19-23, 1999.

A. Rapport and . Mars, Bon usage des aminosides administrés par voie injectable gentamicine, tobramycine, nétilmicine, amikacine -Mise au point, 2011.

G. R. Aronoff, W. M. Bennett, and J. S. Berns, Drug Prescribing in Renal Failure 5

P. A. Philadelphia, American College of Physicians, 2007.

H. Matsuo, J. Hayashi, K. Ono, K. Andoh, Y. Andoh et al., Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality, Antimicrob Agents Chemother, vol.41, issue.12, pp.2597-601, 1997.

K. M. Sowinski, S. J. Magner, A. Lucksiri, M. K. Scott, R. J. Hamburger et al., Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing, Clin J Am Soc Nephrol, vol.3, issue.2, pp.355-61, 2008.

L. Dang and S. Duffull, Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis, J Clin Pharmacol, 2006.

M. M. Teigen, S. Duffull, L. Dang, and D. W. Johnson, Dosing of gentamicin in patients with endstage renal disease receiving hemodialysis, J Clin Pharmacol, vol.46, issue.11, pp.1259-67, 2006.

S. O'shea, S. Duffull, and D. W. Johnson, Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate ?, Semin Dial, vol.22, issue.3, pp.225-255, 2009.

L. Zhuang, Y. He, H. Xia, Y. Liu, S. K. Sy et al., Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semimechanistic pharmacokinetic/pharmacodynamic model, J Antimicrob Chemother, 2016.

A. Mathews and G. R. Bailie, Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services, J Clin Pharm Ther, vol.12, issue.5, pp.273-91, 1987.

M. K. Lacy, D. P. Nicolau, C. H. Nightingale, and R. Quintiliani, The pharmacodynamics of aminoglycosides, Clin Infect Dis, vol.27, issue.1, pp.23-30, 1998.

R. S. Rea and B. Capitano, Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med, vol.28, pp.596-603, 2007.

L. Drgona, M. Paul, and G. Bucaneve, The need for aminoglycosides in combination with ?-lactams for high-risk, febrile neutropaenic patients with leukaemia, Eur J Cancer, vol.43, issue.5, pp.13-22, 2007.

M. Paul, I. Benury-silbiger, and K. Soares-weiser, Betalactam monotherapy versus ß-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systématic review and meta-analysis of randomised trials, BMJ, vol.328, pp.668-672, 2004.

M. Paul, L. Silbiger, and S. Grozinsky, Betalactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis, Cochrane Database Syst Rev, vol.25, issue.1, p.3344, 2006.

J. A. Martínez, N. Cobos-trigueros, and A. Soriano, Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to Gram-negative microorganisms, Antimicrob Agents Chemother, vol.54, issue.9, pp.3590-3596, 2010.

G. Habib, B. Hoen, and P. Tornos, Guidelines on the prevention, and treatment of infective endocarditis (new version 2009): the task force on the prevention, diagnosis and treatment of infective endocarditis of the European Society of Cardiology (ESC), Eur Heart J, vol.30, pp.2369-2413, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00465409

R. Garraffo, H. B. Drugeon, P. Dellamonica, E. Bernard, and P. Lapalus, Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity, Antimicrob Agents Chemother, vol.34, issue.4, pp.614-635, 1990.

G. G. Zhanel, D. J. Hoban, and G. K. Harding, The postantibiotic effect: a review of in vitro and in vivo data, DICP, vol.25, issue.2, pp.153-63, 1991.

A. Buxbaum and A. Georgopoulos, Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans. nfection, pp.459-64, 1996.

B. Fantin, J. Leggett, S. Ebert, and W. A. Craig, Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model, Antimicrob Agents Chemother, vol.35, issue.7, pp.1413-1435, 1991.

G. L. Daikos, V. T. Lolans, and G. G. Jackson, First-exposure adaptative résistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use, Antimicrob Agents Chemother, vol.35, pp.117-123, 1991.

R. K. Chandrakanth, S. Raju, and S. A. Patil, Amonoglycosides-resistance mechanismsin multidrug-resistant Staphylococcus aureus clinical isolates, Curr Microbiol, vol.56, pp.558-562, 2008.

. Duszynska, Therapeutic drug monitoring of amikacin in septic patients, Crit. Care Lond. Engl, vol.17, p.165, 2013.

C. Bartal, Pharmacokinetic dosing of aminoglycosides : a controlled trial, Am J

. Med, , vol.114, pp.194-198, 2003.

H. Hanberger, Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA), Scand J Infect Dis, vol.45, issue.3, pp.161-75, 2013.

W. Picard, Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock, Antimicrob Agents Chemother, vol.58, issue.12, pp.7468-74, 2014.

E. W. Mueller and B. A. Boucher, The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients, Surg Infect (Larchmt), vol.10, issue.6, pp.563-70, 2009.

B. J. Mcgrath, K. C. Lamp, and M. J. Rybak, Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model, Antimicrob Agents Chemother, 1993.

A. Lautrette, F. Coudoré, and B. Souweine, Principes de l'adaptation posologique des antibiotiques lors d'une épuration extrarénale en réanimation, Réanimation juin, vol.19, issue.4, pp.339-346, 2010.

R. F. Eyler and B. A. Mueller, Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease, vol.17, pp.392-403, 2010.

P. Gailiunas, M. Dominguez-moreno, L. M. Lowrie, E. G. Gottlieb, M. N. Merrill et al.,

, Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy, Arch Intern Med, vol.138, issue.11, pp.1621-1625, 1978.

L. Feldman, S. Efrati, E. Eviatar, R. Abramsohn, I. Yarovoy et al.,

J. Weissgarten, Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by Nacetylcysteine. Kidney Int, vol.72, pp.359-63, 2007.

O. Kamel-mohamed, I. M. Wahba, S. Watnick, S. B. Earle, W. M. Bennett et al., Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen, Clin J Am Soc Nephrol, vol.2, issue.4, pp.694-703, 2007.

A. Veinstein, N. Venisse, J. Badin, M. Pinsard, R. Robert et al., Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered, Antimicrob Agents Chemother, vol.57, issue.2, pp.977-82, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00944357

N. Allou, A. J. Levy, Y. Bouteau, A. Caujolle, M. Delmas et al., Assessment of the National French recommendations regarding the dosing regimen of 8mg/kg of gentamicin in patients hospitalised in intensive care units, Anaesth Crit Care Pain Med, vol.35, issue.5, p.331, 2016.

E. De-montmollin, L. Bouadma, N. Gault, B. Mourvillier, E. Mariotte et al.,

, mg/kg total body weight regimen, vol.40, pp.998-1005, 2014.

F. S. Taccone, P. F. Laterre, H. Spapen, T. Dugernier, I. Delattre et al., Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock, Crit Care, vol.14, issue.2, p.53, 2010.

R. Gálvez, C. Luengo, R. Cornejo, J. Kosche, C. Romero et al., Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity, Int J Antimicrob Agents, vol.38, issue.2, pp.146-51, 2011.

M. Bouras, L. Floch, R. Asehnoune, K. Roquilly, and A. , Administration des antibiotiques en réanimation, Congrés d'actualisation SFAR 2017

C. Roger, B. Nucci, N. Molinari, S. Bastide, G. Saissi et al.,

, Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentration, Int J Antimicrob Agents, vol.46, issue.1, pp.21-28, 2015.